BOSTON, June 19, 2014 /PRNewswire/ -- PAREXEL
International (NASDAQ: PRXL), a leading global biopharmaceutical
services organization, today announced that it has won a 2014 Gold
Quill Merit Award from the International Association of Business
Communicators (IABC). The award recognizes achievement in
driving business performance and employee engagement through
successful communication planning and execution. IABC is a global
network of more than 14,000 professionals in 70 countries committed
to improving organizational effectiveness through strategic
communication.
"PAREXEL recognizes that a highly engaged workforce is essential
for fulfilling our mission of helping our customers prevent and
cure disease," said Diana Martin,
Vice President of Corporate Communications, PAREXEL. "As a
result, we've made internal communications a high priority. Winning
a Gold Quill Award is a prestigious recognition of our
customer-focused approach to employee engagement."
In February 2014, PAREXEL launched
a new corporate branding initiative that highlights the Company's
proven approach to help simplify the drug development journey for
clients. Concurrently, the Company renewed its internal focus
on fostering a performance-driven, customer-centric culture across
the organization.
"The PAREXEL brand is a reflection of the dedicated people
behind it," said Christopher Tama,
Worldwide Head of Marketing, PAREXEL. "Our communications help
enhance our customer focus by further unifying us as a
company. As a result, we are better able to work together as
one PAREXEL to fulfill our continued commitment to customers: "Your
Journey. Our Mission.™"
For more than 40 years, IABC's Gold Quill Awards have recognized
excellence in strategic communications worldwide. Sponsored by
Towers Watson, it is the only international awards program for
business communications. The competitive program attracts
nominations from companies in diverse industries. Winners are
selected for leading initiatives that address corporate and
audience needs and make a meaningful business impact.
About PAREXEL International
PAREXEL International
Corporation is a leading global biopharmaceutical services
organization, providing a broad range of knowledge-based contract
research, consulting, medical communications, and technology
solutions and services to the worldwide pharmaceutical,
biotechnology and medical device industries. Committed to providing
solutions that expedite time-to-market and peak-market penetration,
PAREXEL has developed significant expertise across the development
and commercialization continuum, from drug development and
regulatory consulting to clinical pharmacology, clinical trials
management, medical education and reimbursement. PAREXEL
Informatics provides advanced technology solutions, including
medical imaging, to facilitate the clinical development process.
Headquartered near Boston,
Massachusetts, PAREXEL operates in 75 locations in 50
countries around the world, and has approximately 15,335
employees. For more information about PAREXEL International
visit www.PAREXEL.com.
PAREXEL and "Your Journey. Our Mission." are trademarks or
registered trademarks of PAREXEL International Corporation or its
affiliates.
This release contains "forward-looking" statements regarding
future results and events. For this purpose, any
statements contained herein that are not statements of historical
fact may be deemed forward-looking statements. Without
limiting the foregoing, the words "believes," "anticipates,"
"plans," "expects," "intends," "appears," "estimates," "projects,"
"will," "would," "could," "should," "targets," and similar
expressions are also intended to identify forward-looking
statements. The forward-looking statements in this release
involve a number of risks and uncertainties. The Company's
actual future results may differ significantly from the results
discussed in the forward-looking statements contained in this
release. Important factors that might cause such a difference
include, but are not limited to, risks associated with: actual
operating performance; actual expense savings and other operating
improvements resulting from recent and anticipated restructurings;
the loss, modification, or delay of contracts which would, among
other things, adversely impact the Company's recognition of revenue
included in backlog; the Company's dependence on certain industries
and clients; the Company's ability to win new business, manage
growth and costs, and attract and retain employees; the Company's
ability to complete additional acquisitions, and to integrate newly
acquired businesses including the recent acquisitions of LIQUENT,
Inc. and HERON Group Ltd., Inc., or enter into new lines of
business; the impact on the Company's business of government
regulation of the drug, medical device and biotechnology
industry; consolidation within the pharmaceutical industry and
competition within the biopharmaceutical services industry; the
potential for significant liability to clients and third parties;
the potential adverse impact of health care reform; and the effects
of exchange rate fluctuations and other international economic,
political, and other risks. Such factors and others are
discussed more fully in the section entitled "Risk Factors" of the
Company's Quarterly Report on Form 10-Q for the quarter ended
March 31, 2014 as filed with the
Securities and Exchange Commission (SEC) on May 2, 2014, which "Risk Factors" discussion is
incorporated by reference in this press release. The Company
specifically disclaims any obligation to update these
forward-looking statements in the future. These
forward-looking statements should not be relied upon as
representing the Company's estimates or views as of any date
subsequent to the date of this press release.
Contacts:
Diana Martin,
Vice President, Corporate Communications
PAREXEL International
Tel: +1 781-434-5516
Email: Diana.Martin@PAREXEL.com
Matthew Briggs
PAN Communications
Tel: +1 617-502-4300
Email: PAREXEL@pancomm.com
SOURCE PAREXEL International